Treatments for HER2 positive breast cancer reviewed

A ‘real world ‘ review of trastuzumab use during the Herceptin Program has shown duration of treatment increased between 2001 and 2015. The review by the University of NSW found duration of therapy increased from a median of 15.0 months during the early phase of the program 2001-2008 to 18.4 months between 2009 and 2015. About ...